Van Eck Associates Corp Alkermes Plc. Transaction History

Van Eck Associates Corp

$80.1 Billion
Q3 2024

A detailed history of Van Eck Associates Corp transactions in Alkermes Plc. stock. As of the latest transaction made, Van Eck Associates Corp holds 104,986 shares of ALKS stock, worth $2.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

104,986

Previous 74,988 40.0%

Holding current value

$2.95 Million

Previous $1.81 Million 61.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	BUY	$23.01 - $28.55 $690,253 - $856,442	29,998 Added 40.0%	104,986 $2.92 Million
Q2 2024 Jul 31, 2024	BUY	$23.21 - $27.24 $1.74 Million - $2.04 Million	74,988 New	74,988 $1.81 Million
Q2 2019 Aug 07, 2019	SELL	$21.47 - $37.33 $34,416 - $59,839	-1,603 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$28.4 - $36.49 $56 - $72	2 Added 0.12%	1,603 $58,000
Q4 2018 Feb 12, 2019	BUY	$27.94 - $44.61 $838 - $1,338	30 Added 1.91%	1,601 $47,000
Q3 2018 Nov 13, 2018	SELL	$38.6 - $46.12 $4.81 Million - $5.75 Million	-124,701 Reduced 98.76%	1,571 $67,000
Q2 2018 Aug 13, 2018	BUY	$40.56 - $51.36 $228,312 - $289,105	5,629 Added 4.67%	126,272 $5.2 Million
Q1 2018 May 11, 2018	SELL	$53.61 - $67.26 $2.71 Million - $3.39 Million	-50,473 Reduced 29.5%	120,643 $6.99 Million
Q4 2017 Feb 12, 2018	SELL	$47.69 - $55.39 $4.31 Million - $5.01 Million	-90,435 Reduced 34.58%	171,116 $9.37 Million
Q3 2017 Nov 09, 2017	SELL	$49.16 - $54.45 $42,080 - $46,609	-856 Reduced 0.33%	261,551 $13.3 Million
Q2 2017 Aug 11, 2017	BUY	N/A	262,407	262,407 $15.2 Million

Others Institutions Holding ALKS

# of Institutions

364

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.61B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Alkermes Plc. Transaction History